Early intensive treatment gives better outcomes

New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.

Treating MS in pregnancy

MS affects at least twice as many more women than men, and it often strikes at an age when many people are thinking about starting or growing their families.

Advances in research increase rate of MS treatment changes

Studies show that improved MS medications and advances in MRI technology have led to an increased rate of doctors changing courses of MS treatment and a reduced tolerance of any sign of disease activity, with doctors more readily switching treatments in cases of low disease activity.

The winding path of MS progression

How the biological processes cause progression in different types of MS.

First therapy to treat pediatric MS approved in US

Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS

Siponimod offers hope for people with secondary progressive MS

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Daclizumab withdrawn from market over safety concerns

Disappointing results from CCSVI treatment trial

Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

Professor Per Soelberg Sørensen wins prestigious Charcot award for research in multiple sclerosis

Prof. Sørensen, one of the world’s prominent clinical neurologists in multiple sclerosis, recognised for lifetime achievement in improving understanding and treatment of MS.